Protecting corneal cells in Fuchs endothelial corneal dystrophy
Modulating Ferroptosis in Fuchs Endothelial Corneal Dystrophy
Researchers aim to stop a type of iron-driven cell death in people with Fuchs corneal dystrophy to help preserve corneal cells and vision.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11290789 on NIH RePORTER |
What this research studies
This project focuses on ferroptosis, an iron-related form of cell death that appears to kill corneal endothelial cells in Fuchs disease. Scientists will study tissue from people with Fuchs and use laboratory models to track iron levels, fat (lipid) damage, and expression of a ferroptosis marker called transferrin receptor. They will also explore how guttae (the bumps seen in Fuchs) and ultraviolet-A light exposure promote this cell damage. The goal is to identify targets or treatments that could protect corneal cells and slow or stop disease progression.
Who could benefit from this research
Good fit: People diagnosed with Fuchs endothelial corneal dystrophy, especially those in early or progressive stages, are the most likely candidates for related clinical or tissue-donation activities.
Not a fit: People whose corneas are already at end-stage failure and require immediate transplant may not benefit directly from these early-stage laboratory-focused efforts.
Why it matters
Potential benefit: If successful, the work could lead to medical treatments or protective strategies that preserve corneal endothelial cells and reduce the need for corneal transplants in people with Fuchs.
How similar studies have performed: This approach is relatively new: emerging lab and tissue data support ferroptosis as a cause of cell loss in Fuchs, but there are not yet proven patient treatments based on it.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Greiner, Mark Aaron — University of Iowa
- Study coordinator: Greiner, Mark Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.